Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Milirone lactate is a
phosphodiesterase
inhibitor that is used in the acute phase of congestive heart failure. It is available in ready-to-use intravenous piggybacks at a concentration of 200 micrograms/mL and in 10-mL and 20-mL vials at a concentration of 1 mg/mL. The stability of milrinone lactate at highter concentrations of 400, 600, and 800 micrograms/mL in 5% dextrose injection and 0.9% sodium chloride injection was studied. The solutions were prepared in polyvinyl chloride bags and aliquots of 10mL were withdrawn initially and after one, three and seven days at room and refrigerator temperatures under normal light. The aliquots were stored at -20 deg C and analyzed for potency using a high-performance liquid chromatography proceure. Both intraday and interday variations of the external standard were less than 4%. Stablility was defined as 90% or greater of the original concentration remaining.
Milrinone lactate
prepared in either 5% dextrose injection or 0.9% sodium chloride injection at concentrations of 400, 600, and 800 micrograms/mL is stable at room or refrigerated temperature for 14 days.
...
PMID:Stability of Milrinone Lactate in 5% Dextrose Injection and 0.9% Sodium Chloride Injection at Concentrations of 400, 600, and 800 micrograms/mL. 2398 50